Delcath Systems (DCTH) Expected to Announce Quarterly Earnings on Wednesday

Delcath Systems (NASDAQ:DCTH) is anticipated to announce its Q2 2025 earnings results before the market opens on Wednesday, August 6th. Analysts expect the company to announce earnings of $0.02 per share and revenue of $22.84 million for the quarter.

Delcath Systems (NASDAQ:DCTH) last released its quarterly earnings results on Thursday, May 8th. The company reported $0.03 earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.07). The firm had revenue of $19.80 million for the quarter, compared to the consensus estimate of $16.83 million. Delcath Systems had a negative return on equity of 29.44% and a negative net margin of 26.38%. On average, analysts expect Delcath Systems to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Delcath Systems Trading Down 1.5%

NASDAQ:DCTH opened at $10.59 on Monday. The stock has a market cap of $368.85 million, a P/E ratio of -21.18 and a beta of 0.82. The stock’s 50-day moving average is $13.54 and its 200-day moving average is $13.74. Delcath Systems has a 1-year low of $7.17 and a 1-year high of $18.23.

Institutional Trading of Delcath Systems

An institutional investor recently raised its position in Delcath Systems stock. Millennium Management LLC lifted its position in shares of Delcath Systems, Inc. (NASDAQ:DCTH) by 34.1% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 422,066 shares of the company’s stock after purchasing an additional 107,391 shares during the quarter. Millennium Management LLC owned 1.21% of Delcath Systems worth $5,373,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 61.12% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on DCTH. Wall Street Zen upgraded Delcath Systems from a “hold” rating to a “buy” rating in a report on Saturday. HC Wainwright reiterated a “buy” rating and issued a $29.00 target price (up from $24.00) on shares of Delcath Systems in a report on Friday, May 23rd. Finally, Stephens reiterated an “overweight” rating and issued a $25.00 target price on shares of Delcath Systems in a report on Monday, June 23rd. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Delcath Systems currently has a consensus rating of “Buy” and a consensus target price of $24.00.

Delcath Systems Company Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.